Literature DB >> 24136364

Impact of myocardial viability assessed by myocardial perfusion imaging on ventricular tachyarrhythmias in cardiac resynchronization therapy.

David Žižek1, Marta Cvijić, Luka Ležaić, Barbara Gužič Salobir, Igor Zupan.   

Abstract

BACKGROUND: The presence of myocardial fibrosis is associated with ventricular tachyarrhythmia (VT) occurrence irrespective of cardiomyopathy etiology. The aim of our study was to evaluate the impact of global and regional viability on VTs in patients undergoing cardiac resynchronization therapy (CRT).
METHODS: Fifty-seven patients with advanced heart failure (age 62.3 ± 10.2; 38 men; 24 ischemic etiology) were evaluated using single-photon emission computed tomography myocardial perfusion imaging before CRT defibrillator device implantation. Global myocardial viability was determined by the number of viable segments in a 20-segment model. Regional viability was calculated as the mean tracer activity in the corresponding segments at left ventricular (LV) lead position. LV lead segments were determined at implant venography using 2 projections (left anterior oblique 30 and right anterior oblique 30) of coronary sinus tributaries. Patients were followed 30 (24-34) months for the occurrence of VTs.
RESULTS: VTs were registered in 18 patients (31.6%). Patients without VTs had significantly more viable segments (17.6 ± 2.35 vs 14.2 ± 4.0; P = .002) and higher regional myocardial viability at LV lead position (66.1% ± 10.3% vs 54.8% ± 11.4% of tracer activity; P = .001) than those with VTs. In multivariate logistic regression models, the number of viable segments (OR = 0.66; 95% confidence interval (CI) 0.53-0.85; P = .001) and regional viability (OR = 0.90; 95% CI 0.85-0.97; P = .003) were the only independent predictors of VT occurrence.
CONCLUSION: Global and regional myocardial viability are independently related to the occurrence of VTs in patients after CRT.

Entities:  

Mesh:

Year:  2013        PMID: 24136364     DOI: 10.1007/s12350-013-9795-y

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  37 in total

1.  Increase in ventricular tachycardia frequency after biventricular implantable cardioverter defibrillator upgrade.

Authors:  Jose M Guerra; Jianyi Wu; John M Miller; William J Groh
Journal:  J Cardiovasc Electrophysiol       Date:  2003-11

2.  Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients.

Authors:  Claudia Ypenburg; Martin J Schalij; Gabe B Bleeker; Paul Steendijk; Eric Boersma; Petra Dibbets-Schneider; Marcel P M Stokkel; Ernst E van der Wall; Jeroen J Bax
Journal:  Eur Heart J       Date:  2006-11-22       Impact factor: 29.983

3.  Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy.

Authors:  Paul W X Foley; Shajil Chalil; Kayvan Khadjooi; Nick Irwin; Russell E A Smith; Francisco Leyva
Journal:  Eur J Heart Fail       Date:  2010-11-04       Impact factor: 15.534

Review 4.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

5.  Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial.

Authors:  Valentina Kutyifa; Wojciech Zareba; Scott McNitt; Jagmeet Singh; William Jackson Hall; Slava Polonsky; Ilan Goldenberg; David T Huang; Bela Merkely; Paul J Wang; Arthur J Moss; Helmut Klein
Journal:  Eur Heart J       Date:  2012-10-10       Impact factor: 29.983

6.  Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging.

Authors:  Zainab Samad; Allen E Atchley; Mark A Trimble; Jie-Lena Sun; Linda K Shaw; Robert Pagnanelli; Ji Chen; Ernest V Garcia; Ami E Iskandrian; Eric J Velazquez; Salvador Borges-Neto
Journal:  J Nucl Cardiol       Date:  2010-11-17       Impact factor: 5.952

7.  Implantable cardioverter-defibrillator patients who are upgraded and respond to cardiac resynchronization therapy have less ventricular arrhythmias compared with nonresponders.

Authors:  Joep Thijssen; C Jan Willem Borleffs; Victoria Delgado; Johannes B van Rees; Eline A Q Mooyaart; Rutger J van Bommel; Lieselot van Erven; Eric Boersma; Jeroen J Bax; Martin J Schalij
Journal:  J Am Coll Cardiol       Date:  2011-11-22       Impact factor: 24.094

8.  Functional significance of regional ischemic contraction abnormalities.

Authors:  J S Forrester; H L Wyatt; P L Da Luz; J V Tyberg; G A Diamond; H J Swan
Journal:  Circulation       Date:  1976-07       Impact factor: 29.690

9.  Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death.

Authors:  Alida E Borger van der Burg; Jeroen J Bax; Eric Boersma; Ernest K J Pauwels; Ernst E van der Wall; Martin J Schalij
Journal:  Circulation       Date:  2003-10-06       Impact factor: 29.690

10.  Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death.

Authors:  Jonathan P Piccini; John R Horton; Linda K Shaw; Sana M Al-Khatib; Kerry L Lee; Ami E Iskandrian; Salvador Borges-Neto
Journal:  Circ Cardiovasc Imaging       Date:  2008-09-17       Impact factor: 7.792

View more
  2 in total

1.  The complexities of resynchronizing scar.

Authors:  Kenneth C Bilchick
Journal:  J Nucl Cardiol       Date:  2013-10-25       Impact factor: 5.952

Review 2.  State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies.

Authors:  Balint Laczay; Divyang Patel; Richard Grimm; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.